Here’s whether Abbott Laboratories (ABT) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.35% over 10 days); RSI 65 — healthy momentum range; 3-month momentum positive (+13.1%). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -18.0%. Currently 25.0% off its 52-week high. Score: +1/7.
ABT is trading below its 200-day MA ($109.02) — a key warning sign the longer-term trend is under pressure. An RSI of 64.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -18.0% compares to +16.5% for SPY (trailed the market by 34.4%). The current 25.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $8,203 today
vs. S&P 500 (SPY) — same period trailed market by 34.4%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($109.02)
✓Above 50-day MA ($91.28)
✓RSI(14) neutral zone (30–70) — currently 64.8
✗Positive return (-18.0%)
!Within 10% of period high (−25.0%)
Period Range $103.06
$81.97$137.49
RSI (14) 64.8
0 · OversoldOverbought · 100
Key Metrics
Price$103.06
Period Return-18.0%
Period High$137.49
Period Low$81.97
Drawdown−25.0%
MA-50$91.28
MA-200$109.02
RSI (14)64.8
Avg Volume (30d)14.1M
vs. SPYtrailed by 34.4%
Return Rank#680 of 999
Trend Signals
Price is below the 200-day moving average ($109.02)